Ensurge Micropower (ENSU) Q1 2025 earnings summary

Executive summary

• Transitioned from intensive R&D to commercial readiness after six years and $400 million in equity-funded investment, with no public funding.

• Achieved key technology milestones, including successful demonstration and shipment of microbatteries on 10μm substrate and 11-layer/10μm batteries, confirming fast charging and C-pulse charge capabilities.

• Commercial pipeline exceeds 120 potential customers, with medtech, wearables, and IoT sectors gaining traction.

• Strategic focus on joint development agreements, licensing, and scaling manufacturing to accelerate commercialization and fund technology development.

• Transitioned to 24/7 manufacturing shifts and implemented roll-to-roll (R2R) production, filing critical IP for process innovation.

Financial highlights

• Over $400 million invested to date, all through equity, with no public funding.

• Reported zero revenue in Q1 2025, down from USD 20 thousand in Q1 2024.

• Operating costs decreased to USD 1,441 thousand (Q1 2025) from USD 3,278 thousand (Q1 2024), mainly due to capitalization of R&D costs.

• Net loss narrowed to USD 1,907 thousand (USD 0.005 per share) from USD 3,759 thousand (USD 0.007 per share) year-over-year.

• Cash balance at March 31, 2025 was USD 3,087 thousand, including USD 1,600 thousand restricted cash.

Outlook and guidance

• Targeting delivery of 150,000 batteries to a lead customer by end of 2025, with commercial production of 28-layer batteries expected after customer validation and regulatory certification.

• Plans to expand deposition and laser processing, execute targeted licensing agreements, and pursue new JDAs.

• Focus on scaling manufacturing, cost optimization, and leveraging the San Jose battery incubation center for co-development.

• Anticipates faster development cycles for future battery variants due to improved manufacturing processes.

• Well positioned to capture value through licensing and product commercialization in upcoming quarters.